Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

What Was Tested

In this phase 3 trial, researchers set out to test Tirzepatide.

It had four arms (groups): Group IC (experimental), Group II (active comparator), Group IA (active comparator) and Group 1B (active comparator).

The registry classes the interventions as drug.

More on the Plan

A subgroup of patients from group 1 will be invited to participate in a sub-study which lasts for 6 months and aims at exploring the metabolic/molecular mechanisms responsible for the study results.

The selection of subjects to each subgroup will be done randomly and the end of sub-study, subjects will continue therapy and follow-up from month 6 on in the main study.

Who Took Part

Enrollment: 256 planned participants were the target.

It was open to people of any sex aged from 18 years up to 75 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Ability of subject to understand and the willingness to sign a written informed consent document. Males and females; Age 18-75 years. Drug naïve or receiving metformin monotherapy. Willingness to adhere to the investigational product regimen. Stable body weight over the preceding 3 months.

The full record lists 9 inclusion and 9 exclusion criteria; among the exclusions: positive anti-gad (antibodies to glutamic acid decarboxylase); pregnancy or plan of becoming pregnant; evidence of proliferative diabetic retinopathy,.

How the Study Was Run

The set-up was randomized, parallel-group and open-label.

The participants were allocated by chance, so the Tirzepatide group and the comparison group should start out alike.

The Tirzepatide group and the comparison group ran side by side rather than switching.

Nothing was hidden in this open-label Tirzepatide study: the participants and staff both knew the treatment.

It started in 2024-11-07 with completion listed for 2029-04-30.

It ran at 2 sites in United States (2).

Its stated primary purpose is other.

What Was Measured

It also tracked 3 secondary outcomes, for example Change in insulin sensitivity, Change in Beta Cell Function and Change in body weight.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Tirzepatide in 256 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, all human trials.